MME and chronic kidney disease: Exclusion of CKD patients is particularly widespread in trials evaluating β-blockers, RAAS inhibitors (RAASi), and angiotensin receptor/neprilysin inhibitors (ARNI), limiting evidence to support or not the use of these agents in CKD patients with HF [31].